Reviewing Inovio Pharmaceuticals (INO) and Its Peers

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Inovio Pharmaceuticals to related companies based on the strength of its risk, institutional ownership, analyst recommendations, dividends, earnings, profitability and valuation.

Insider & Institutional Ownership

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Inovio Pharmaceuticals and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inovio Pharmaceuticals 1 1 4 0 2.50
Inovio Pharmaceuticals Competitors 9959 15361 45766 1602 2.54

Inovio Pharmaceuticals presently has a consensus target price of $6.33, suggesting a potential upside of 259.85%. As a group, “Biotechnology” companies have a potential upside of 114.68%. Given Inovio Pharmaceuticals’ higher probable upside, research analysts clearly believe Inovio Pharmaceuticals is more favorable than its peers.

Volatility and Risk

Inovio Pharmaceuticals has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals’ peers have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.

Earnings & Valuation

This table compares Inovio Pharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Inovio Pharmaceuticals $60,000.00 -$84.95 million -3.26
Inovio Pharmaceuticals Competitors $744.18 million $10.27 million -17.98

Inovio Pharmaceuticals’ peers have higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Inovio Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inovio Pharmaceuticals N/A -28,886.30% -75.67%
Inovio Pharmaceuticals Competitors -12,519.20% -215.47% -31.42%

Summary

Inovio Pharmaceuticals peers beat Inovio Pharmaceuticals on 8 of the 13 factors compared.

Inovio Pharmaceuticals Company Profile

(Get Free Report)

Inovio Pharmaceuticals, Inc. is a biotechnology company developing DNA medicines, including treatments intended to stimulate the body’s immune response to cancers and infectious diseases. Its research has focused on therapeutic and preventive applications, with candidates targeting conditions such as human papillomavirus (HPV)-related disease. The company’s technology uses synthetic DNA plasmids designed to prompt cells to produce targeted antigens. Inovio has also developed its CELLECTRA platform, which uses electroporation to help deliver DNA medicines into cells.

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.